Who Paid My Doc
Omidria
Drug Ophthalmology
NDC 62225-600-04
General payments
$1,273,792
Research payments
$582,520
Through program year 2025, $1,273,792 in general payments and $582,520 in research payments were reported against Omidria (Ophthalmology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $77,860 | 931 |
| 2025 | Research | $152,153 | 10 |
| 2024 | General | $57,923 | 1,663 |
| 2024 | Research | $159,028 | 17 |
| 2023 | General | $160,884 | 2,186 |
| 2022 | General | $113,944 | 1,489 |
| 2021 | General | $170,106 | 1,438 |
| 2021 | Research | $50,000 | 2 |
| 2020 | General | $224,852 | 985 |
| 2020 | Research | $35,340 | 1 |
| 2019 | General | $468,222 | 2,728 |
| 2019 | Research | $186,000 | 1 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 32 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 39 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
11,420 general · 31 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.